Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2011-04-12
2011-04-12
Spector, Lorraine (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C514S002600, C514S007600, C514S008300, C514S017700
Reexamination Certificate
active
07922999
ABSTRACT:
A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.
REFERENCES:
patent: 5676928 (1997-10-01), Klaveness et al.
patent: 5720720 (1998-02-01), Laske et al.
patent: 5731284 (1998-03-01), Williams
patent: 5733875 (1998-03-01), Martin
patent: 5741778 (1998-04-01), Martin et al.
patent: 5830857 (1998-11-01), Carnahan et al.
patent: 5843473 (1998-12-01), Woodle et al.
patent: 5846565 (1998-12-01), Brem et al.
patent: 6042579 (2000-03-01), Elsberry
patent: 6180613 (2001-01-01), Kaplitt et al.
patent: 6245330 (2001-06-01), Horellou et al.
patent: RE37410 (2001-10-01), Brem
patent: 6632427 (2003-10-01), Finiels et al.
patent: 6790824 (2004-09-01), Unsicker et al.
patent: 6800281 (2004-10-01), Aebischer et al.
patent: 6815431 (2004-11-01), Tuszynski
patent: 7018628 (2006-03-01), Sarkis et al.
patent: 7157435 (2007-01-01), Tuszynski et al.
patent: 7182944 (2007-02-01), Bankiewicz
patent: 7244423 (2007-07-01), Tuszynski
patent: 2002/0114780 (2002-08-01), Bankiewicz et al.
patent: 2002/0141980 (2002-10-01), Bankiewicz et al.
patent: 2002/0182249 (2002-12-01), Papahadjopoulos
patent: 2002/0187127 (2002-12-01), Bankiewicz
patent: 2004/0028673 (2004-02-01), Netzer et al.
patent: 2004/0209810 (2004-10-01), Gill et al.
patent: 2005/0112065 (2005-05-01), Drummond et al.
patent: 2005/0137134 (2005-06-01), Gill et al.
patent: 2005/0180955 (2005-08-01), Bankiewicz et al.
patent: 2006/0008909 (2006-01-01), Cullis et al.
patent: 2006/0073101 (2006-04-01), Oldfield et al.
patent: WO93/06116 (1993-04-01), None
patent: WO2004/031348 (2004-04-01), None
patent: 2005/120548 (2005-12-01), None
patent: 2006/044115 (2006-04-01), None
Nutt et al., Neurology, 60(1): 69-73, Jan. 14, 2003.
Lang et al., Annals of Neurology, 59:459-466, Jan. 20, 2006.
Nguyen et al., NeuroReport, 12(9):1961-1964, Jul. 3, 2001.
Yasuhara et al., Acta Medica Okayama, 61(2): 51-56, Apr. 2007.
Lapchak et al., Brain Research, 777:153-160, 1997.
Boado et al., Drug Metabolism and Disposition, 37: 2299-2304, 2009.
Morrison et al., J Neurosurgery, 107: 74-83, Jul. 2007.
Patel et al., Ann Neurol, 57:298-302, Feb. 2005.
Akerud; et al., “Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons”, Journal of Neurochemistry (1999), 73(1):70-8.
Allen et al, Clinical relevance of the neurotrophins and their receptors. Clinical Science 2006;110:175-91.
Bankiewicz et al, Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164(1):2-14.
Bankiewicz et al, Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol 2005;197:363-72.
Bankiewicz et al, Practical Aspects of the Development of ex Vivo and in Vivo Gene Therapy for Parkinson's Disease. Experimental Neurology 1997;144:147-56.
Beck; et al., “Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain”, Nature (1995), 373:339-341.
Blesch; et al., Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons, Molecular Therapy (2005), 11:916-925.
Bobo et al, Convection-enhanced delivery of macromolecules in the brain. PNAS 1994;91(6):2076-80.
Brain Activity: Academic and Research News 5(1). Neuro-Oncology Symposium: “Advances in Research and Treatment in the 21st Century” San Francisco, California, Sep. 14, 2002; CED of liposomes was first mentioned in the talk presented by Dr. Bankiewicz.
Brem; et al., “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas”, J Neurosurg (1991), 74(3):441-6.
Bruce et al, Intracerebral clysis in a rat glioma model. Neurosurgery 2000;46(3):683-91.
Chen et al, A realistic brain tissue phantom for intraparenchymal infusion studies. J Neurosurg 2004;101:314-22.
Chen et al, Combination Therapy with Irinotecan and Protein Kinase C Inhibitors in Malignant Glioma. Cancer 2003;97(9):2363-2373.
Chen et al, Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg 2005;103:311-19.
Chen et al, Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999;90(2):315-20.
Choi-Lundberg; et al., “Applications of gene therapy to neurological diseases and injuries”, In: Stem Cell Biology and Gene Therapy. New York, NY: Wiley-Liss, Inc.; 1998; p. 503-5. (Summary Only).
Connor; et al., “The role of neuronal growth factors in neurodegenerative disorders of the human brain”, Brain Res Brain Res Rev (1998), 27(1):1-39. (Abstract Only).
Creddon; et al., “Neurturin share receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons”, Proceedings of the National Academy of Sciences (1997), 94:7018-23.
Cunningham et al, Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant 2000;9(5):585-94.
Daadi et al, Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport 2006;17(2):201-4.
Durbec; et al, “GDNF signalling through the ret receptor tyrosine kinase”, Nature (1996), 381:789-93.
Eslamboli et al, Assessment of GDNF in primate models of Parkinson's disease: Comparison with human studies. Rev Neurosci 2005;16:303-10.
Forgie et al, Differences and developmental changes in the responsiveness of PNS neurons to GDNF and neurturin. Mol Cell Neurosci 1999;13:430-40.
Friedman et al, The emerging role of Irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 2003;97(9s):2359-62.
Gill et al, Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9(5):589-95.
Groothuis, The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol 2000;2(1):45-59.
Hadaczek et al, Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Human Gene Therapy 2006;17:1-12.
Hadaczek et al, The “Perivascular Pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 2006;14(1):69-78.
Hamilton; et al., “Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin”, Exp Neurol (2001), 168:155-61.
Haroun et al, Local drug delivery. Current Opinion in Oncology 2000;12:187-193.
Hefti et al, Neurotrophic factor therapy for neurodegenerative diseases. J Neurobiol 1994;25:1418-35.
Henderson; et al., “GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle”, Science (1994), 266:1062-1064.
Hoane; et al., “Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor”, Experimental Neurology (1999), 160(1):235-43.
Hoffer et al, Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994;182:107-11.
Horger; et al., “Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons”, The Journal of Neuroscience (1998), 18(13):4929-37.
Hudson et al, Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bill 1995;36:425-432.
Jackson; et al., “Comparison of Segmentation Techniques Applied to MR Images of Convectively Delivered Gadolinium-labeled Liposomes in Monkey Brains”, Proceedings fro
Bozicevic Field & Francis LLP
MacFarlane Stacey
Sherwood Pamela J.
Spector Lorraine
The Regents of the University of California
LandOfFree
Administration of growth factors for the treatment of CNS... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of growth factors for the treatment of CNS..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of growth factors for the treatment of CNS... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699564